The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 23, 2025

Filed:

Aug. 10, 2022
Applicant:

Novartis Pharma Ag, Basel, CH;

Inventors:

Shankar Venkatraman, Lansdale, PA (US);

Jason Katz, Newton, MA (US);

William R. Roush, Boston, MA (US);

Hans Martin Seidel, Concord, MA (US);

Assignee:

NOVARTIS PHARMA AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/40 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 407/12 (2006.01); C07D 417/12 (2006.01); C07D 451/02 (2006.01); C07D 471/04 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
C07D 209/40 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 417/12 (2013.01); C07D 451/02 (2013.01); C07D 471/04 (2013.01); C07D 487/08 (2013.01); C07B 2200/05 (2013.01);
Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.


Find Patent Forward Citations

Loading…